Cyclo Operating Income from 2010 to 2024

CYTHW Stock

USD 0.13 0.01 7.14%

Cyclo Therapeutics Operating Income yearly trend continues to be fairly stable with very little volatility. Operating Income is likely to outpace its year average in 2024. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Cyclo Therapeutics generates from its operations. View All Fundamentals

Operating Income

First Reported

2000-09-30

Previous Quarter

-5.6 M

Current Value

-8.3 M

Quarterly Volatility

1.7 M

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Check Cyclo Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cyclo Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.3 K, Interest Expense of 181.7 K or Total Revenue of 995.2 K, as well as many indicators such as Price To Sales Ratio of 25.33, Dividend Yield of 0.0 or PTB Ratio of 7.66. Cyclo financial statements analysis is a perfect complement when working with Cyclo Therapeutics Valuation or Volatility modules.

Check out the analysis of Cyclo Therapeutics Correlation against competitors.

For more information on how to buy Cyclo Stock please use our How to Invest in Cyclo Therapeutics guide.

Latest Cyclo Therapeutics' Operating Income Growth Pattern

Below is the plot of the Operating Income of Cyclo Therapeutics over the last few years. Operating Income is the amount of profit realized from Cyclo Therapeutics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cyclo Therapeutics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Cyclo Therapeutics' Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cyclo Therapeutics' overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Cyclo Operating Income Regression Statistics

	Arithmetic Mean	(6,698,888)
	Coefficient Of Variation	(107.86)
	Mean Deviation	6,017,994
	Median	(4,205,887)
	Standard Deviation	7,225,451
	Sample Variance	52.2T
	Range	20.4M
	R-Value	(0.94)
	Mean Square Error	6.9T
	R-Squared	0.88
	Slope	(1,513,021)
	Total Sum of Squares	730.9T

Cyclo Operating Income History

	2024	-19 M
	2023	-20.1 M
	2022	-15.6 M
	2021	-14.3 M
	2020	-9 M
	2019	-7.4 M
	2018	-4.3 M

Other Fundumenentals of Cyclo Therapeutics

Non Operating Income Net Other

Cyclo Therapeutics Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments	Current Deferred Revenue	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt	Short Long Term Debt	Net Tangible Assets
Total Assets		0.85	-0.96	-0.71	0.81	0.68	0.73	0.99	0.4	-0.28	-0.42	-0.3	-0.52	0.8	0.7	0.91	0.9	-0.79	-0.67	0.65	-0.48
Total Stockholder Equity	0.85		-0.89	-0.3	0.45	0.79	0.28	0.84	-0.04	-0.23	-0.43	-0.23	-0.33	0.45	0.53	0.95	0.95	-0.65	-0.39	0.3	0.01
Net Debt	-0.96	-0.89		0.63	-0.79	-0.74	-0.62	-0.98	-0.22	0.2	0.37	0.22	0.63	-0.73	-0.72	-0.96	-0.95	0.77	0.58	-0.53	0.32
Retained Earnings	-0.71	-0.3	0.63		-0.91	-0.3	-0.94	-0.74	-0.82	0.24	0.29	0.28	0.7	-0.98	-0.65	-0.46	-0.44	0.77	0.89	-0.92	0.72
Accounts Payable	0.81	0.45	-0.79	-0.91		0.44	0.93	0.85	0.58	-0.24	-0.13	-0.27	-0.76	0.91	0.76	0.61	0.59	-0.67	-0.71	0.75	-0.67
Net Receivables	0.68	0.79	-0.74	-0.3	0.44		0.23	0.7	-0.14	-0.25	-0.07	-0.25	-0.46	0.41	0.31	0.79	0.8	-0.38	-0.45	0.31	0.03
Total Liab	0.73	0.28	-0.62	-0.94	0.93	0.23		0.73	0.79	-0.23	-0.21	-0.28	-0.55	0.91	0.63	0.44	0.42	-0.63	-0.76	0.86	-0.85
Total Current Assets	0.99	0.84	-0.98	-0.74	0.85	0.7	0.73		0.38	-0.24	-0.39	-0.26	-0.63	0.83	0.73	0.92	0.91	-0.81	-0.68	0.65	-0.46
Short Term Debt	0.4	-0.04	-0.22	-0.82	0.58	-0.14	0.79	0.38		-0.18	-0.29	-0.22	-0.28	0.76	0.34	0.05	0.02	-0.54	-0.75	0.82	-0.77
Intangible Assets	-0.28	-0.23	0.2	0.24	-0.24	-0.25	-0.23	-0.24	-0.18		-0.33	0.99	0.34	-0.21	-0.18	-0.13	-0.13	0.17	0.18	-0.18	0.08
Common Stock	-0.42	-0.43	0.37	0.29	-0.13	-0.07	-0.21	-0.39	-0.29	-0.33		-0.31	-0.08	-0.41	-0.3	-0.48	-0.48	0.71	0.45	-0.38	0.12
Short Term Investments	-0.3	-0.23	0.22	0.28	-0.27	-0.25	-0.28	-0.26	-0.22	0.99	-0.31		0.35	-0.24	-0.21	-0.13	-0.12	0.19	0.22	-0.25	0.1
Current Deferred Revenue	-0.52	-0.33	0.63	0.7	-0.76	-0.46	-0.55	-0.63	-0.28	0.34	-0.08	0.35		-0.68	-0.58	-0.46	-0.46	0.57	0.54	-0.49	0.27
Capital Surpluse	0.8	0.45	-0.73	-0.98	0.91	0.41	0.91	0.83	0.76	-0.21	-0.41	-0.24	-0.68		0.69	0.6	0.58	-0.85	-0.91	0.89	-0.66
Property Plant Equipment	0.7	0.53	-0.72	-0.65	0.76	0.31	0.63	0.73	0.34	-0.18	-0.3	-0.21	-0.58	0.69		0.61	0.6	-0.68	-0.46	0.46	-0.26
Net Invested Capital	0.91	0.95	-0.96	-0.46	0.61	0.79	0.44	0.92	0.05	-0.13	-0.48	-0.13	-0.46	0.6	0.61		1.0	-0.73	-0.49	0.4	-0.18
Net Working Capital	0.9	0.95	-0.95	-0.44	0.59	0.8	0.42	0.91	0.02	-0.13	-0.48	-0.12	-0.46	0.58	0.6	1.0		-0.72	-0.48	0.38	-0.15
Capital Stock	-0.79	-0.65	0.77	0.77	-0.67	-0.38	-0.63	-0.81	-0.54	0.17	0.71	0.19	0.57	-0.85	-0.68	-0.73	-0.72		0.78	-0.69	0.35
Long Term Debt	-0.67	-0.39	0.58	0.89	-0.71	-0.45	-0.76	-0.68	-0.75	0.18	0.45	0.22	0.54	-0.91	-0.46	-0.49	-0.48	0.78		-0.95	0.51
Short Long Term Debt	0.65	0.3	-0.53	-0.92	0.75	0.31	0.86	0.65	0.82	-0.18	-0.38	-0.25	-0.49	0.89	0.46	0.4	0.38	-0.69	-0.95		-0.66
Net Tangible Assets	-0.48	0.01	0.32	0.72	-0.67	0.03	-0.85	-0.46	-0.77	0.08	0.12	0.1	0.27	-0.66	-0.26	-0.18	-0.15	0.35	0.51	-0.66

Click cells to compare fundamentals

About Cyclo Therapeutics Financial Statements

Cyclo Therapeutics investors use historical fundamental indicators, such as Cyclo Therapeutics' Operating Income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cyclo Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-20.1 M	-19 M
Non Operating Income Net Other	153.9 K	136.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cyclo Operating Income from 2010 to 2024

Latest Cyclo Therapeutics' Operating Income Growth Pattern

Cyclo Operating Income Regression Statistics

Cyclo Operating Income History

Other Fundumenentals of Cyclo Therapeutics

Cyclo Therapeutics Operating Income component correlations

About Cyclo Therapeutics Financial Statements

Also Currently Popular

Additional Tools for Cyclo Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY